C4 Therapeutics reports FY2023 net loss of $132.5M; cash runway extended into 2027

C4 Therapeutics, Inc.

2023-FY EPS reported -$2.67 revenue$20,756,000

Net loss for FY2023 was $132.5M ($2.67 per share) vs $128.2M ($2.62) in FY2022.
Revenue fell to $20.8M from $31.1M, mainly due to end of Calico collaboration.
Cash, equivalents and marketable securities at Dec 31, 2023: $281.7M; proforma ~$330M with Jan 2024 inflows, funding into 2027.
Workforce reduced ~30% in Jan 2024; trials for CFT7455 and CFT1946 continue, data expected 2H2024.
Collaborations: Merck deal up to $2.5B milestone potential; Betta paid $25M, CTA approved in China.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.65

C4 Therapeutics, Inc. reported financial results for the year ended December 31, 2023.

Period: the year ended December 31, 2023
Result: reported results

Exact text from the filing

On February 22, 2024, C4 Therapeutics, Inc. (the “ Company ”) issued a press release announcing its financial results and business highlights for the quarter and fiscal year ended December 31, 2023.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

C4 Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-24-006142

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.